Drugs / Spironolactone
Spironolactone
also known as
Aldactone · spiro · SPL · Abbolactone · Carospir · Diatensec · Espironolactona · Gx spironol · +18 more
Small molecule targets NR3C2, RXRG via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Qaialdo | — | 2023-05-26 | europa.eu ↗ |
| Label expansion | US (FDA) | ALDACTONE | — | 1981-06-30 | fda.gov ↗ |
| Approved | US (FDA) | ALDACTONE | — | 1960-01-21 | fda.gov ↗ |
Trials 151 · started per year
today
US approved 1960
EU approved 2023
1
1
1
2
4
4
7
5
5
5
2
9
6
3
8
7
8
5
3
7
7
7
7
12
7
8
3
6
19591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05995392 | Aug 2023 → Feb 2024 | dry eye syndrome | Richard W Yee, MD | Unknown | No outcome recorded |
| Phase 0 | NCT04723862 | Nov 2021 → Oct 2025 overdue | polycystic ovary syndrome | University of Virginia | Recruiting | No outcome recorded |
| Phase 0 | NCT04075149 | Dec 2019 → Sep 2024 | anovulation, polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
| Phase 0 | NCT03929718 | Apr 2019 → Sep 2025 overdue | atrial fibrillation | Piedmont Healthcare | Active not recruiting | No outcome recorded |
| Phase 19 trials · 2 missed | ||||||
| Phase 1 | NCT05807139 | Jul 2023 → Dec 2026 expected | alcohol-related disorders | National Institute on Drug Abuse (NIDA) | Recruiting | No outcome recorded |
| Phase 1 | NCT04283656 | Jan → Oct 2022 | HIV infectious disease | Thomas Jefferson University | Completed | Missed primary |
| Phase 1 | NCT03953209 | Mar 2020 → Jan 2021 | hyperpigmentation of the skin | Medical University of South Carolina | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03909529 | Mar → Apr 2019 | — | CMP Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03777319 | Dec 2018 → Sep 2021 | Duchenne muscular dystrophy | Kevin Flanigan | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01598740 | Jun → Sep 2012 | heart failure | Sorbent Therapeutics | Completed | Missed primary |
| Phase 1 | NCT01314898 | Mar → Jun 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01083290 | Apr 2010 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00240656 | Oct 2005 → May 2006 | pulmonary arterial hypertension | Hebei Medical University | Completed | No outcome recorded |
| Phase 1/24 trials · 1 met primary | ||||||
| Phase 1/2 | NCT07483177 | May 2026 → May 2028 expected | thoracic aortic aneurysm | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04901975 | Feb 2021 → Jun 2026 | univentricular heart | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 1/2 | NCT03576755 | Jan 2019 → Jul 2023 | metabolic dysfunction-associated steatohepatitis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT01552044 | Jan 2012 → Jan 2013 | central serous chorioretinopathy | French National Institute of Health and Medical Research | Completed | Met primary |
| Phase 231 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT07715318 | Dec 2026 → Dec 2027 expected | anemia | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07645300 | Oct 2026 → Mar 2032 expected | chronic kidney disease | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07473895 | Apr → Oct 2026 expected | acne | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07041281 | Oct 2025 → Dec 2027 expected | preeclampsia | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03593317 | Dec 2024 → Dec 2027 expected | arrhythmogenic right ventricular cardiomyopathy | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 2 | NCT06004830 | Nov 2023 → Jan 2026 | HIV infectious disease, alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT05394142 | May 2022 → Apr 2025 | polycystic ovary syndrome | Fundació Sant Joan de Déu | Unknown | No outcome recorded |
| Phase 2 | NCT05222191 | Feb 2022 → Dec 2023 | chronic kidney disease, hypertensive disorder | Indiana Institute for Medical Research | Unknown | No outcome recorded |
| Phase 2 | NCT05754684 | Jan 2022 → Dec 2025 overdue | neuroblastoma | Hong Kong Children's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04633005 | Nov 2021 → Oct 2025 | heart failure | University of Texas Southwestern Medical Center | Completed | Met primary |
| Phase 2 | NCT04760717 | Mar 2021 → Feb 2026 overdue | intracerebral hemorrhage, ischemic stroke | Yale University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04643691 | Sep 2020 → Dec 2021 | COVID-19, acute respiratory distress syndrome | Assistance Publique Hopitaux De Marseille | Terminated | No outcome recorded |
| Phase 2 | NCT04190433 | Sep 2020 → Apr 2023 | breast carcinoma, lymphoma, sarcoma | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04327232 | May 2018 → May 2022 | atrial fibrillation | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT04393493 | Jul 2017 → Apr 2020 | cardio-renal syndrome | Hospital Civil de Guadalajara | Completed | Missed primary |
| Phase 2 | NCT02556450 | Jan 2016 → Sep 2018 | heart failure | ACS Biomarker | Completed | No outcome recorded |
| Phase 2 | NCT02299726 | May 2015 → May 2018 | heart failure | Indiana University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02497300 | Mar 2015 → Jul 2021 | chronic kidney disease, proteinuria | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03744767 | Sep 2014 → Sep 2015 | wet macular degeneration | Dr Irmela MANTEL | Completed | No outcome recorded |
| Phase 2 | NCT01712620 | Jan 2014 → Dec 2026 expected | pulmonary arterial hypertension | National Institutes of Health Clinical Center (CC) | Recruiting | No outcome recorded |
| Phase 2 | NCT01867294 | Aug 2012 → May 2014 | metastatic malignant neoplasm, toxic dermatosis | Academic and Community Cancer Research United | Completed | No outcome recorded |
| Phase 2 | NCT01407471 | Sep 2011 → May 2012 | skin atrophy | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT01294319 | Jan 2011 → Aug 2016 | glucocorticoid resistance | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 2 | NCT01667614 | May 2010 → Mar 2012 | diabetic kidney disease, essential hypertension, type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01069510 | Feb 2010 → Jun 2016 | congenital heart disease, endomyocardial fibrosis, heart failure | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT01147523 | Jan → Nov 2010 | metabolic dysfunction-associated steatohepatitis | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 2 | NCT00430794 | Mar 2007 → Dec 2008 | hypertensive disorder | Sheffield Teaching Hospitals NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00175617 | Sep 2005 → Mar 2009 | androgenetic alopecia | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00381134 | Jul 2003 → Dec 2006 | diabetes mellitus, diabetic kidney disease, hypertensive disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00004311 | Jul 1989 → Jan 1996 | acanthosis nigricans, polycystic ovary syndrome | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT00001202 | Jan 1985 → Jan 2004 | precocious puberty | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 2/37 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT06678685 | Oct 2024 → Dec 2026 expected | — | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05676684 | Sep 2022 → Nov 2024 | diastolic heart failure | University of Porto | Completed | Met primary |
| Phase 2/3 | NCT03981861 | Jul 2016 → Jul 2018 | polycystic ovary syndrome | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 2/3 | NCT02585843 | Nov 2015 → Mar 2017 | heart failure | Columbia University | Completed | No outcome recorded |
| Phase 2/3 | NCT02531412 | Oct 2015 → Aug 2017 | cancer | National Cancer Institute of Mexico | Unknown | No outcome recorded |
| Phase 2/3 | NCT00141778 | Apr 2005 → Jul 2010 | atrial fibrillation | Vanderbilt University | Completed | Missed primary |
| Phase 2/3 | NCT00106561 | Jan 2002 → Sep 2004 | diabetic kidney disease, glomerulonephritis, proteinuria | Melbourne Health | Completed | No outcome recorded |
| Phase 322 trials · 3 missed | ||||||
| Phase 3 | NCT07043634 | Jun → Dec 2025 | — | Sarfez Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06204640 | Mar 2024 → Jan 2028 expected | atrial fibrillation | University Hospital, Caen | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05092984 | Jun 2022 → Mar 2026 overdue | rheumatoid arthritis | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 3 | NCT05230901 | Feb 2022 → Jun 2025 | aortic valve stenosis | University Medical Center Goettingen | Unknown | No outcome recorded |
| Phase 3 | NCT04980716 | Jun 2021 → Jan 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT04826822 | Feb → Jul 2021 | COVID-19, viral pneumonia | Chita State Regional Clinical Hospital Number 1 | Unknown | No outcome recorded |
| Phase 3 | NCT06413082 | Feb 2021 → Jul 2023 | essential hypertension | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase 3 | NCT04465123 | Aug 2020 → Jul 2022 | acute kidney injury, heart failure | Chiang Mai University | Unknown | No outcome recorded |
| Phase 3 | NCT04424134 | May → Jul 2020 | COVID-19 | Lomonosov Moscow State University Medical Research and Educational Center | Unknown | No outcome recorded |
| Phase 3 | NCT03551548 | Feb 2019 → Jul 2021 | atrial fibrillation | University Hospital, Caen | Unknown | No outcome recorded |
| Phase 3 | NCT04727073 | Nov 2018 → Oct 2024 | symptomatic heart failure | Charite University, Berlin, Germany | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03334682 | Jan 2018 → Feb 2023 | acne | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03206658 | Aug 2017 → Dec 2019 | acute kidney injury | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | No outcome recorded |
| Phase 3 | NCT03314493 | Nov 2014 → Nov 2016 | calcinosis, coronary artery disorder | Professor Fernando Figueira Integral Medicine Institute | Completed | No outcome recorded |
| Phase 3 | NCT01853553 | Jul 2013 → Jan 2017 | autosomal dominant polycystic kidney disease | University of Colorado, Denver | Completed | Missed primary |
| Phase 3 | NCT01062763 | Mar 2010 → Mar 2012 | resistant hypertension, type 2 diabetes mellitus | Ib Abildgaard Jacobsen | Completed | No outcome recorded |
| Phase 3 | NCT01059136 | Feb 2010 → Aug 2014 | myocardial infarction | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT00604006 | Sep 2008 → Aug 2014 | heart failure | Monash University | Completed | No outcome recorded |
| Phase 3 | NCT00865501 | Mar 2008 → Dec 2009 | essential hypertension | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00523757 | Aug 2007 → Apr 2010 | heart failure | Justin Ezekowitz | Completed | No outcome recorded |
| Phase 3 | NCT00094302 | Aug 2006 → Jun 2013 | congestive heart failure | Carelon Research | Completed | Missed primary |
| Phase 3 | NCT00123955 | Apr 2005 → Jun 2009 | diastolic heart failure | Wake Forest University | Completed | No outcome recorded |
| Phase 451 trials · 4 met primary · 5 missed | ||||||
| Phase 4 | NCT07687160 | Sep 2026 → Feb 2028 expected | hypertensive disorder | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07513883 | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT06523465 | Sep 2024 → Dec 2025 overdue | hypertensive disorder, primary aldosteronism | Third Military Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06021860 | Jun 2024 → Mar 2025 | — | CMP Development, LLC | Unknown | No outcome recorded |
| Phase 4 | NCT06035978 | Mar 2024 → Apr 2026 | symptomatic heart failure | University Hospital Ostrava | Unknown | No outcome recorded |
| Phase 4 | NCT06499948 | Feb 2024 → Nov 2025 | Alport syndrome | Stefan Lujinschi | Completed | No outcome recorded |
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT06005259 | Oct 2023 → Oct 2025 | chemotherapy-induced toxicity, heart failure, neoplasm | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT05688579 | Apr 2023 → Dec 2026 expected | hyperaldosteronism, hypertensive disorder | Nanfang Li | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05637853 | Oct 2022 → Aug 2024 overdue | symptomatic heart failure | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04522739 | Sep 2022 → Sep 2025 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04853355 | Jul → Sep 2022 | diabetic macular edema | Wake Forest University Health Sciences | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04582383 | Mar 2022 → Feb 2026 overdue | acne | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04205136 | Mar 2022 → Apr 2023 | obstructive sleep apnea syndrome | University of Michigan | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04455178 | Sep 2020 → Dec 2023 | essential hypertension | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04142788 | Aug 2020 → Dec 2022 | congestive heart failure | NHS Greater Glasgow and Clyde | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03953950 | Oct 2019 → Sep 2020 | end stage renal failure | Chiang Mai University | Unknown | No outcome recorded |
| Phase 4 | NCT03597035 | Jul 2018 → Jul 2020 | type 2 diabetes mellitus | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02948998 | May 2018 → Oct 2019 | hypertrophic cardiomyopathy | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT03344159 | Apr 2018 → Aug 2022 | heart failure, intrinsic cardiomyopathy, pulmonary hypertension, primary, 2, pulmonary hypertension, primary, 3 +1 | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03757117 | Oct 2016 → Mar 2018 | HIV infectious disease | Asociación Civil Impacta Salud y Educación, Peru | Completed | No outcome recorded |
| Phase 4 | NCT02169089 | Jan 2016 → Apr 2022 | atherosclerosis | University Hospitals Cleveland Medical Center | Completed | Met primary |
| Phase 4 | NCT02832973 | Sep 2015 → Dec 2017 | resistant hypertension | Sao Jose do Rio Preto Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT02673463 | Jan 2015 → Dec 2018 | atrial fibrillation | University of Birmingham | Unknown | Missed primary |
| Phase 4 | NCT02883400 | Dec 2014 → Jan 2018 | liver disorder | Wake Forest University Health Sciences | Completed | Missed primary |
| Phase 4 | NCT02502981 | Jun 2014 → Feb 2018 | cardio-renal syndrome, chronic kidney disease | University Hospital Birmingham | Unknown | No outcome recorded |
| Phase 4 | NCT02429388 | May 2014 → Oct 2015 | heart failure | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01973335 | Nov 2013 → Apr 2017 | heart failure | Hasselt University | Completed | Missed primary |
| Phase 4 | NCT01855334 | Sep 2013 → Jul 2018 | end stage renal failure | Brigham and Women's Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00328809 | Jun 2013 → Jun 2017 | congestive heart failure, end stage renal failure | State University of New York - Upstate Medical University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01843309 | May 2013 → Mar 2015 | fungal infectious disease | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Terminated | No outcome recorded |
| Phase 4 | NCT01602861 | Feb 2013 → Apr 2021 | disease related to solid organ transplantation | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02426099 | Oct 2011 → Oct 2012 | resistant hypertension, type 2 diabetes mellitus | Sobngwi Eugene | Completed | Met primary |
| Phase 4 | NCT01468571 | Jul 2011 → Jul 2015 | pulmonary hypertension | Baylor College of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01128101 | Mar 2011 → Dec 2012 | kidney failure | UPECLIN HC FM Botucatu Unesp | Unknown | No outcome recorded |
| Phase 4 | NCT01198496 | Oct 2010 → Dec 2017 | essential hypertension, stroke disorder | Biomedis International Ltd. | Unknown | Missed primary |
| Phase 4 | NCT01944384 | Aug → Dec 2010 | diastolic heart failure | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00870402 | Mar → Dec 2009 | diabetic kidney disease | Universidad de los Andes, Chile | Unknown | No outcome recorded |
| Phase 4 | NCT01687699 | Apr → Dec 2008 | end stage renal failure | Dialysis Outcomes Heart Failure Aldactone Study Group | Completed | Met primary |
| Phase 4 | NCT00574119 | Dec 2007 → Jul 2012 | dilated cardiomyopathy, heart failure | Vanderbilt University | Completed | No outcome recorded |
| Phase 4 | NCT00879060 | Nov 2007 → Nov 2011 | hypertrophic cardiomyopathy | Tufts Medical Center | Completed | Missed primary |
| Phase 4 | NCT00548912 | Oct 2007 → Oct 2008 | chronic renal failure syndrome | Dawnmarie DeFazio | Withdrawn | No outcome recorded |
| Phase 4 | NCT00335413 | Jun 2006 → Apr 2007 | hypertensive disorder | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT01089309 | May 2004 → Jun 2007 | arteriosclerosis disorder | Wolfson Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00664222 | Jan 2004 → Dec 2005 | heart failure | Tottori University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00663195 | Jan 2004 → Dec 2005 | heart failure | Tottori University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00317954 | Sep 2003 → Jul 2005 | diabetic kidney disease | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00306696 | Oct 2002 → Jan 2004 | diabetes mellitus | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT00188045 | Apr 1995 → Dec 2003 | alcoholic liver cirrhosis | University Hospital, Angers | Terminated | No outcome recorded |
| Phase 4 | NCT00277693 | — | — | Universidad de los Andes, Chile | Unknown | No outcome recorded |
| Phase not applicable23 trials · 1 met primary | ||||||
| — | NCT07020104 | Jan 2025 → Dec 2039 expected | chronic kidney disease | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| — | NCT07415811 | Jul → Dec 2024 overdue | HIV infectious disease | University of Sao Paulo General Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06091475 | Dec 2023 → Aug 2026 overdue | dilated cardiomyopathy, heart failure | Imperial College London | Recruiting | No outcome recorded |
| — | NCT03626506 | Feb 2019 → Aug 2020 | hypertensive disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT03291145 | Jun 2017 → Jun 2018 | long QT syndrome, sudden arrhythmia death syndrome | Herlev and Gentofte Hospital | Completed | No outcome recorded |
| — | NCT01422759 | Dec 2016 → Dec 2024 | obesity disorder, polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
| — | NCT03174288 | Aug 2015 → May 2019 | type 1 diabetes mellitus | University of Virginia | Completed | No outcome recorded |
| — | NCT02047422 | Jan 2014 → Feb 2016 | congestive heart failure | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT02190318 | Nov 2013 → Dec 2015 | chronic kidney disease | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| — | NCT02417896 | Apr 2013 → Jul 2015 | acute kidney injury | Instituto Nacional de Cardiologia Ignacio Chavez | Unknown | No outcome recorded |
| — | NCT02129621 | May 2010 → Nov 2012 | cardiovascular disorder | Central Hospital, Nancy, France | Completed | No outcome recorded |
| — | NCT00811486 | Jan 2009 → Jul 2010 | heart failure, pulmonary hypertension | University of Colorado, Denver | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00865124 | Sep 2008 → Aug 2013 | type 2 diabetes mellitus, vascular disorder | Brigham and Women's Hospital | Completed | Met primary |
| — | NCT00689598 | Mar 2008 → Mar 2011 | atrial fibrillation | Taichung Veterans General Hospital | Unknown | No outcome recorded |
| — | NCT00429897 | Aug 2006 → Jul 2007 | hypertensive disorder | University of Cambridge | Unknown | No outcome recorded |
| — | NCT00842140 | Feb 2006 → Jan 2009 | polycystic ovary syndrome | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00276289 | Jan → Jun 2006 | idiopathic hypercalciuria, potassium deficiency disease | Indiana University | Completed | No outcome recorded |
| — | NCT00295347 | Dec 2005 → Jun 2008 | major depressive disorder | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT00125437 | Sep 2005 → Sep 2009 | congestive heart failure | Hebei Medical University | Terminated | No outcome recorded |
| — | NCT00528385 | Mar 2005 → ? | chronic kidney disease, proteinuria | Medical University of Gdansk | Completed | No outcome recorded |
| — | NCT00211081 | Nov 2004 → Jun 2008 | congenital heart malformation | Emory University | Completed | No outcome recorded |
| — | NCT00860340 | Feb 2003 → Oct 2006 | congestive heart failure | University of Toledo Health Science Campus | Completed | No outcome recorded |
| — | NCT00498537 | Jan 2003 → Dec 2005 | diabetic kidney disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Comparator or background therapy103 trials | ||||||
| Phase 0 | NCT02689843 Comparator | Feb → Nov 2018 | polycystic ovary syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03068910 Comparator | Jul 2016 → Oct 2025 overdue | polycystic ovary syndrome | University of Virginia | Recruiting | No outcome recorded |
| Phase 1 | NCT06205407 Comparator | Dec 2023 → Mar 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03682497 Comparator | Nov 2018 → Mar 2020 | heart failure | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT02941315 Comparator | Dec 2016 → Oct 2021 | idiopathic cardiomyopathy | RenJi Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01821703 Comparator | May → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01488877 Comparator | Jan → Jul 2012 | diabetic kidney disease | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01103245 Comparator | Mar 2010 → Jul 2012 | diabetes mellitus | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00857909 Comparator | Jan 2009 → Jul 2010 | hypertensive disorder | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 1/2 | NCT07431216 Background | May 2026 → May 2027 expected | glioblastoma | Starlight Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03867682 Background | Jan 2020 → Nov 2023 | acute myeloid leukemia | Actinium Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02575963 Background | Oct 2012 → Nov 2018 | acute myeloid leukemia | Actinium Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT07857772 Comparator | Mar 2027 → May 2028 expected | diastolic heart failure | Baim Institute for Clinical Research | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07539259 Comparator | Dec 2026 → Aug 2029 expected | aortic valve stenosis | University College, London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07304817 Comparator | May 2026 → Feb 2028 expected | chronic kidney disease, heart failure | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 2 | NCT05010707 Comparator | Aug 2021 → Aug 2023 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT04785755 Background | Nov 2017 → Mar 2020 | — | Hala Abd EL-Tawab Ibrahim Radwan | Completed | No outcome recorded |
| Phase 2 | NCT03329443 Comparator | Sep 2017 → Sep 2018 | acute kidney injury, myocardial ischemia | Alhasan Mujtaba Abdul-Wahid | Completed | No outcome recorded |
| Phase 2 | NCT03071263 Background | Jan 2017 → Nov 2018 | resistant hypertension | Relypsa, Inc. | Completed | Met primary |
| Phase 2 | NCT02501213 Comparator | May 2016 → Nov 2017 | cancer | Centre Oscar Lambret | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02235077 Comparator | Dec 2014 → Apr 2016 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT02285920 Comparator | Nov 2014 → Jun 2017 | end stage renal failure | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT02230891 Comparator | Oct 2014 → Dec 2020 | diabetes mellitus, hypertensive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT02236520 Comparator | Sep 2014 → May 2018 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT02194465 Comparator | Aug 2014 → Mar 2015 | essential hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01691053 Comparator | Dec 2012 → Feb 2017 | end stage renal failure | Wuerzburg University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01371747 Background | Jun 2011 → May 2013 | chronic kidney disease, hypertensive disorder | Relypsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01345656 Comparator | May 2011 → May 2012 | heart failure | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01130597 Background | May → Sep 2010 | heart failure | Relypsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01021943 Comparator | Nov 2009 → ? | — | Instituto Nacional de Cardiologia Ignacio Chavez | Suspended | No outcome recorded |
| Phase 2 | NCT00291720 Comparator | Apr 2005 → Dec 2007 | cardiovascular disorder, chronic kidney disease | University Hospital Birmingham | Completed | No outcome recorded |
| Phase 2/3 | NCT02040441 Comparator | Mar 2014 → Nov 2018 | diabetic kidney disease, diabetic retinopathy | Peter Rossing | Completed | No outcome recorded |
| Phase 2/3 | NCT02173288 Background | Jul 2013 → Mar 2016 | cirrhosis of liver | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT01721655 Comparator | Oct 2012 → Dec 2016 | bronchopulmonary dysplasia | West Virginia University Healthcare | Unknown | No outcome recorded |
| Phase 3 | NCT07223502 Comparator | May 2025 → Sep 2026 | hypertensive disorder | Sarfez Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05849766 Comparator | Apr 2023 → May 2024 | dilated cardiomyopathy | October 6 University | Completed | No outcome recorded |
| Phase 3 | NCT03653845 Background | Jul 2018 → Jul 2019 | hypertensive disorder, primary aldosteronism | Third Military Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03048825 Comparator | Feb 2018 → Aug 2024 | ST-elevation myocardial infarction | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02901184 Comparator | Nov 2017 → Dec 2026 expected | diastolic heart failure | Uppsala University | Recruiting | No outcome recorded |
| Phase 3 | NCT03020303 Comparator | Jul 2017 → Mar 2025 | end stage renal failure | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02354352 Comparator | Mar 2015 → May 2018 | Duchenne muscular dystrophy | Ohio State University | Completed | No outcome recorded |
| Phase 3 | NCT02764619 Comparator | Dec 2013 → Feb 2017 | atrial fibrillation | Svendborg Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01882179 Comparator | Nov 2013 → May 2016 | ST-elevation myocardial infarction | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT01848639 Comparator | Jun 2013 → Nov 2022 | end stage renal failure | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT01586442 Comparator | Mar 2012 → Mar 2015 | glucose intolerance, heart failure, type 2 diabetes mellitus | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 3 | NCT00865449 Comparator | Jul 2008 → Dec 2011 | end stage renal failure | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
| Phase 4 | NCT07523867 Comparator | Apr → Oct 2026 expected | diabetic kidney disease, heart failure | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07281014 Comparator | Jan 2026 → Aug 2027 expected | heart failure | Yale University | Recruiting | No outcome recorded |
| Phase 4 | NCT06457074 Comparator | Jun 2024 → Apr 2026 | primary aldosteronism | Chongqing Medical University | Completed | No outcome recorded |
| Phase 4 | NCT06164379 Comparator | Dec 2023 → Dec 2024 | primary aldosteronism | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT05814770 Comparator | May 2023 → Mar 2025 | hypertensive disorder, primary aldosteronism | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT04331691 Comparator | Nov 2020 → May 2024 | resistant hypertension | Yonsei University | Completed | Met primary |
| Phase 4 | NCT03984591 Comparator | Nov 2020 → Dec 2028 expected | systolic heart failure | Bispebjerg Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04618601 Comparator | Oct 2020 → Dec 2021 | heart failure | Laiko General Hospital, Athens | Unknown | No outcome recorded |
| Phase 4 | NCT04100083 Comparator | Sep 2020 → Jun 2021 | hidradenitis suppurativa | Medical University of South Carolina | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04575675 Background | May → Nov 2020 | heart failure, hypotensive disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04062760 Background | Dec 2019 → Dec 2021 | heart failure | University of Parma | Unknown | No outcome recorded |
| Phase 4 | NCT03502031 Comparator | Oct 2018 → Oct 2022 | diabetic kidney disease | James A. Tumlin, MD | Unknown | No outcome recorded |
| Phase 4 | NCT02907749 Comparator | Jan 2018 → Jan 2020 | cirrhosis of liver, portal hypertension | Changqing Yang | Completed | No outcome recorded |
| Phase 4 | NCT02483195 Comparator | Aug 2016 → Aug 2018 | androgenetic alopecia | University of Florida | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT02253394 Comparator | Sep 2015 → Feb 2018 | pulmonary arterial hypertension | Brigham and Women's Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT02046668 Comparator | Nov 2013 → Mar 2015 | osteoarthritis, knee | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT01945801 Comparator | Oct 2013 → Feb 2015 | obstructive sleep apnea syndrome | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT03429946 Comparator | Jul 2013 → Nov 2025 | hypoglycemia | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01774656 Background | Jan 2013 → Dec 2017 | advanced heart failure | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT01643434 Comparator | Aug 2012 → Dec 2013 | hypertensive disorder | Instituto do Coracao | Unknown | No outcome recorded |
| Phase 4 | NCT01510795 Comparator | Jan 2012 → Jun 2013 | chronic renal failure syndrome | Clinical Hospital Merkur | Unknown | No outcome recorded |
| Phase 4 | NCT02053974 Comparator | Sep 2011 → Oct 2012 | cardiomyopathy due to anthracyclines | TC Erciyes University | Completed | No outcome recorded |
| Phase 4 | NCT01388088 Comparator | Sep 2010 → Feb 2012 | hypertensive disorder | Erling Bjerregaard Pedersen | Completed | No outcome recorded |
| Phase 4 | NCT01271374 Comparator | Apr 2010 → Jun 2011 | hypertensive disorder | InVasc Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT02369081 Comparator | May 2009 → Jul 2015 | resistant hypertension | University of Cambridge | Unknown | No outcome recorded |
| Phase 4 | NCT00524615 Comparator | Sep 2007 → Oct 2012 | hypertensive disorder | Jan Vaclavík | Unknown | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00332904 Comparator | Aug 2006 → Jul 2008 | cirrhosis of liver, portal hypertension | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00353652 Comparator | Jan 2005 → Jan 2013 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04495712 Comparator | Jul 2004 → May 2008 | cardiac rhythm disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT00206232 Comparator | Jul 2004 → Jul 2010 | heart failure | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00226109 Comparator | Apr 2004 → Aug 2011 | alcohol dependence, alcoholic cardiomyopathy | University of Aarhus | Suspended | No outcome recorded |
| — | NCT07331220 Background | Dec 2026 → Dec 2028 expected | diastolic heart failure | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07585526 Comparator | Apr 2026 → Mar 2028 expected | chronic kidney disease, metabolic dysfunction-associated steatotic liver disease | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT07130175 Background | Dec 2022 → Dec 2024 | heart failure, polymorphic ventricular tachycardia | Qian Feng | Completed | No outcome recorded |
| — | NCT05501080 Comparator | Sep 2022 → Sep 2025 overdue | primary aldosteronism | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| — | NCT07328230 Comparator | Aug 2022 → Dec 2025 overdue | hyperaldosteronism | Chinese Academy of Medical Sciences, Fuwai Hospital | Recruiting | No outcome recorded |
| — | NCT05287100 Background | Jan 2022 → May 2023 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT04367051 Comparator | Aug 2020 → Dec 2021 | heart failure | Asan Medical Center | Completed | No outcome recorded |
| — | NCT03645642 Background | Sep → Dec 2018 | hepatobiliary disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT03547895 Comparator | Jun 2015 → May 2016 | cirrhosis of liver | Zagazig University | Completed | No outcome recorded |
| — | NCT02364089 Comparator | Apr 2015 → Mar 2022 | adrenal gland disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01953874 Background | Dec 2013 → Dec 2015 | heart failure, sleep apnea syndrome | ResMed | Terminated | No outcome recorded |
| — | NCT01817803 Comparator | Mar 2013 → Jun 2015 | congestive heart failure | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT02039492 Comparator | Sep 2012 → Dec 2015 | resistant hypertension | Parc de Salut Mar | Completed | No outcome recorded |
| — | NCT02167464 Comparator | Jun 2011 → Jan 2015 | hypertensive disorder | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT01195805 Comparator | Aug 2010 → Aug 2015 | essential hypertension | Regional Hospital Holstebro | Completed | No outcome recorded |
| — | NCT01526616 Comparator | May 2010 → May 2011 | polycystic ovary syndrome | University Magna Graecia | Completed | No outcome recorded |
| — | NCT01406015 Comparator | Feb 2009 → Aug 2013 | obesity disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT01897727 Comparator | Jan 2009 → Apr 2012 | hyperaldosteronism, obstructive sleep apnea syndrome, resistant hypertension | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT00709137 Comparator | Oct 2008 → Oct 2010 | hypertensive disorder | VA Salt Lake City Health Care System | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00773084 Comparator | Sep 2008 → Aug 2009 | diastolic heart failure | Texas Tech University Health Sciences Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00224809 Background | Sep 2002 → May 2007 | coronary artery disorder | Baylor Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-07-20 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Spironolactone Tablets USP zyduslife.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-07-20 | Zydus Lifesciences Limited | Zydus receives final approval from the USFDA for Spironolactone Tablets USP zyduslife.com ↗ |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 257 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spironolactone | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗252“Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily)....” NCT07130175 ↗ “One group was treated with mineralocorticoid receptor antagonists(MRAs) (including spironolactone 20-60mg/ day, or eplerenone50-100mg/day, or finerenone 10-20mg/ day) in...” NCT05688579 ↗ “1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible” NCT01882179 ↗ “Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.” NCT04062760 ↗ “The investigators hypothesize that the mineralocorticoid receptor antagonist (MRA), spironolactone, may prevent HF by acting on extracellular matrix remodelling” NCT02556450 ↗ “Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated” NCT01953874 ↗ “Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable).” NCT04142788 ↗ “Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio)” NCT04785755 ↗ “Antiandrogen therapy with spironolactone started at a dose of 50 mg daily and increased every 4 weeks to 200 mg daily” NCT03757117 ↗ “Patients will be randomized (1:1) to renal sympathetic denervation treatment or spironolactone (50mg)” NCT02039492 ↗ |
| Known as | Abbolactone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Aldactone | “Spironolactone (Aldactone) is an antiandrogen that also reduced testosterone synthesis by inhibiting the enzyme 17-hydroxylase.” NCT00001202 ↗4“Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.” NCT03645642 ↗ “100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.” NCT00860340 ↗ “Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®” NCT05849766 ↗ “Aldactone” NCT02417896 ↗ |
| Known as | Carospir | “Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL)” NCT03909529 ↗ |
| Known as | Diatensec | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Espironolactona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Gx spironol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Laractone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | NSC-150399 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Qaialdo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | SC-9420 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spiretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | spiro | “before and after spironolactone (Spiro).” PMID 20550533 ↗ Nov 20101“spironolactone (spiro)/empa” NCT07857772 ↗ |
| Known as | Spiroctan 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spiroctan 25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spiroctan 50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironol | “Spironolactone (Spironol) 25 mg” NCT00528385 ↗ |
| Known as | Spironolactone ARROW | “Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial” NCT03334682 ↗ |
| Known as | Spironolactone ceva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironolactone component of aldactazide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironolactone component of cardalis | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironolactonum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spirospare 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spirospare 25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | SPL | “The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.” NCT02285920 ↗1“Spironolactone (SPL), a mineralocorticoid receptor antagonist” NCT05222191 ↗ |
| Known as | Verospiron | “Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗ |
| Known as | Verospirone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Action | Inhibit | “spironolactone to inhibit the action of androgen” NCT00001202 ↗1“Mineralocorticoid receptor antagonist” CHEMBL1393 ↗ |
| Modality | Small molecule | “the steroidal mineralocorticoid receptor antagonist spironolactone” PMID 40818851 ↗ Aug 2025 |
| Route | Oral | “oral spironolactone” NCT00004311 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor antagonist” CHEMBL1393 ↗ |
| Target | RXRG | “retinoid X receptor gamma (RXRg) agonist spironolactone” NCT05754684 ↗ |